FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136173314> ?p ?o ?g. }

• W3136173314 endingPage "229" @default.
• W3136173314 startingPage "219" @default.
• W3136173314 abstract "The assessment and prevention of cardiovascular risk (CVR) that persists in patients with dyslipidaemia despite treatment and achievement of goals specific to the plasma concentration of cholesterol linked to low density (c-LDL) is a clinical challenge today, and suggests that conventional lipid biomarkers are insufficient for an accurate assessment of CVR. Apart from their lipid content, there are other lipid particle characteristics. The results of this study show that there are a number of lipoprotein compounds that determine atherogenic potential and its influence on the CVR. However, such additional characteristics cannot be analysed by the techniques commonly used in clinical laboratories. Nuclear Magnetic Resonance (NMR), is a technique that allows a detailed analysis to be made of the amount, composition, and size of lipoproteins, as well as providing more information about the detailed status of lipid metabolism and CVR in dyslipidaemia patients. In this article a group of lipidologists from the Spanish Society of Arteriosclerosis review the existing evidence on the atherogenic mechanisms of particles and describe the technical basis and interpretation of the profiles lipoproteins obtained by MRI, with special reference to the test available in Spain (Liposcale®). Likewise, the main patient profiles are defined as such that an analysis would provide information of greater clinical interest. These include: a) Suspected mismatch between lipid concentrations and particles, a common situation in diabetes, obesity, metabolic syndrome, (b) Early atherothrombotic cardiovascular disease (ECVA) or recurrent without CVR factors to justify it; c) Lipid disorders, rare or complex, such as extreme concentrations of c-HDL, and d) Clinical situations where classical analytical techniques cannot be applied, such as very low c-LDL values. La evaluación y prevención del riesgo cardiovascular (RCV) que persiste en los pacientes con dislipidemia a pesar del tratamiento y de haber alcanzado los objetivos específicos de la concentración plasmática de colesterol unido a lipoproteínas de baja densidad (c-LDL) es un reto clínico en la actualidad, y sugiere que los biomarcadores lipídicos convencionales resultan insuficientes para una evaluación precisa del RCV. Más allá de su contenido lipídico, existen otras características propias de las partículas lipoproteicas que determinan su potencial aterogénico y su influencia en el RCV. Sin embargo, dichas características adicionales no pueden ser analizadas por las técnicas utilizadas habitualmente en los laboratorios clínicos. La espectroscopia por resonancia magnética nuclear (RMN), es una técnica que permite un análisis detallado de la cantidad, composición y tamaño de las lipoproteínas y proporciona información más detallada del estado del metabolismo lipídico y del RCV en los pacientes dislipémicos. En este artículo un grupo de lipidólogos de la Sociedad Española de Arteriosclerosis revisa la evidencia existente sobre los mecanismos aterogénicos de las partículas lipoproteicas y describen el fundamento técnico y la interpretación de los perfiles lipoproteicos obtenidos mediante RMN, haciendo especial referencia al test disponible en España (Liposcale®). Así mismo se definen los principales perfiles de pacientes en los que dicho análisis aportaría una información de mayor interés clínico, los cuales son: a) Sospecha de discordancia entre las concentraciones de lípidos y el número de partículas, situación frecuente en la diabetes, la obesidad, el síndrome metabólico y la hipertrigliceridemia; b) Enfermedad cardiovascular aterotrombótica (ECVA) precoz o recurrente sin factores de RCV que la justifiquen; c) Trastornos lipídicos infrecuentes o complejos como las concentraciones extremas de c-HDL, d) Situaciones clínicas en las que las técnicas analíticas clásicas no pueden aplicarse, como los valores de c-LDL muy bajos." @default.
• W3136173314 created "2021-03-29" @default.
• W3136173314 creator A5001084228 @default.
• W3136173314 creator A5003598852 @default.
• W3136173314 creator A5008446495 @default.
• W3136173314 creator A5026292617 @default.
• W3136173314 creator A5030284877 @default.
• W3136173314 creator A5049719217 @default.
• W3136173314 creator A5064239944 @default.
• W3136173314 creator A5072815031 @default.
• W3136173314 creator A5072893859 @default.
• W3136173314 creator A5075389977 @default.
• W3136173314 creator A5089512738 @default.
• W3136173314 date "2020-09-01" @default.
• W3136173314 modified "2023-10-15" @default.
• W3136173314 title "Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®)" @default.
• W3136173314 cites W1515206644 @default.
• W3136173314 cites W1968171440 @default.
• W3136173314 cites W1982456918 @default.
• W3136173314 cites W1987667569 @default.
• W3136173314 cites W1996258616 @default.
• W3136173314 cites W2009883608 @default.
• W3136173314 cites W2012344261 @default.
• W3136173314 cites W2015450538 @default.
• W3136173314 cites W2022525201 @default.
• W3136173314 cites W2030551858 @default.
• W3136173314 cites W2031055477 @default.
• W3136173314 cites W2036765220 @default.
• W3136173314 cites W2040433877 @default.
• W3136173314 cites W2040770080 @default.
• W3136173314 cites W2053585701 @default.
• W3136173314 cites W2085725801 @default.
• W3136173314 cites W2107443630 @default.
• W3136173314 cites W2108169164 @default.
• W3136173314 cites W2109095803 @default.
• W3136173314 cites W2111099202 @default.
• W3136173314 cites W2116404316 @default.
• W3136173314 cites W2123027967 @default.
• W3136173314 cites W2128361838 @default.
• W3136173314 cites W2132196134 @default.
• W3136173314 cites W2135867187 @default.
• W3136173314 cites W2140866104 @default.
• W3136173314 cites W2152354184 @default.
• W3136173314 cites W2154836846 @default.
• W3136173314 cites W2157854383 @default.
• W3136173314 cites W2164324917 @default.
• W3136173314 cites W2164346577 @default.
• W3136173314 cites W2166648967 @default.
• W3136173314 cites W2169338584 @default.
• W3136173314 cites W2172232070 @default.
• W3136173314 cites W2219267274 @default.
• W3136173314 cites W2227482939 @default.
• W3136173314 cites W2236488484 @default.
• W3136173314 cites W2322985394 @default.
• W3136173314 cites W2337193712 @default.
• W3136173314 cites W2402599050 @default.
• W3136173314 cites W2485118186 @default.
• W3136173314 cites W2501649131 @default.
• W3136173314 cites W2530844910 @default.
• W3136173314 cites W2599772444 @default.
• W3136173314 cites W2620579455 @default.
• W3136173314 cites W2730951372 @default.
• W3136173314 cites W2783047364 @default.
• W3136173314 cites W2783963608 @default.
• W3136173314 cites W2787647639 @default.
• W3136173314 cites W2794925464 @default.
• W3136173314 cites W2795926289 @default.
• W3136173314 cites W2800713945 @default.
• W3136173314 cites W2916953725 @default.
• W3136173314 cites W2950630380 @default.
• W3136173314 cites W2981767898 @default.
• W3136173314 cites W4252004908 @default.
• W3136173314 cites W4253173808 @default.
• W3136173314 cites W4254967137 @default.
• W3136173314 doi "https://doi.org/10.1016/j.artere.2020.04.001" @default.
• W3136173314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32798078" @default.
• W3136173314 hasPublicationYear "2020" @default.
• W3136173314 type Work @default.
• W3136173314 sameAs 3136173314 @default.
• W3136173314 citedByCount "7" @default.
• W3136173314 countsByYear W31361733142021 @default.
• W3136173314 countsByYear W31361733142022 @default.
• W3136173314 countsByYear W31361733142023 @default.
• W3136173314 crossrefType "journal-article" @default.
• W3136173314 hasAuthorship W3136173314A5001084228 @default.
• W3136173314 hasAuthorship W3136173314A5003598852 @default.
• W3136173314 hasAuthorship W3136173314A5008446495 @default.
• W3136173314 hasAuthorship W3136173314A5026292617 @default.
• W3136173314 hasAuthorship W3136173314A5030284877 @default.
• W3136173314 hasAuthorship W3136173314A5049719217 @default.
• W3136173314 hasAuthorship W3136173314A5064239944 @default.
• W3136173314 hasAuthorship W3136173314A5072815031 @default.
• W3136173314 hasAuthorship W3136173314A5072893859 @default.
• W3136173314 hasAuthorship W3136173314A5075389977 @default.
• W3136173314 hasAuthorship W3136173314A5089512738 @default.
• W3136173314 hasBestOaLocation W31361733141 @default.
• W3136173314 hasConcept C126322002 @default.
• W3136173314 hasConcept C126838900 @default.

• next